Congress by Design appointment

Posted: Friday, October 28, 2011

WIN Consortium Appoints Congress by design as Congress Management Agency For 4th WIN Symposium in Personalized Cancer Medicine

Paris, October 28, 2011 - WIN Consortium, initiated by Cancer Institute Gustave Roussy (France) and University of Texas MD Anderson Cancer Center (USA), has appointed Congress by design formerly MCCM Meeting Management B.V. as its congress management agency for the 4th WIN Symposium in Personalized Cancer Medicine, to be held in Paris, France, June 28-29, 2012. This symposium will provide a forum for discussion of the rapidly advancing field of personalized cancer medicine.

MCCM Meeting Management is a congress management agency based in Harmelen (Utrecht), The Netherlands, having ample experience in managing international medical congresses and symposia as well as meetings in other areas. MCCM Meeting Management will support the 4th WIN Symposium over a wide range of activities in the preparation and execution of the symposium at Palais des Congrès in Paris. MCCM Meeting Management will also serve as the symposium secretariat for the 4th WIN Symposium and will be the primary point of contact for all matters related to the Symposium.

MCCM Meeting Management was established in 2006 by its current managing partners, Marinus Lobbezoo, Ph.D., and Nicolette van Erven, after having collaborated in a range of congresses and other live meetings over a period of 12 years. Among the congresses they have managed are well-known meetings in oncology, including the NCI-EORTC Symposium on New Drugs in Cancer Therapy (continued as the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics as of 1999) and the International Congress on Targeted Anticancer Therapies.

About the WIN Consortium

The WIN Consortium ( is a joint initiative of Institut Gustave Roussy (France) and University of Texas - MD Anderson Cancer Center (USA) which brings together 17 cancer centers around the world, the National Breast Cancer Foundation, Sage Bionetworks and three technology partners: Agilent Technologies, GE Healthcare and Life Technologies The mission of WIN is to conduct worldwide innovative clinical trials in order to accelerate the pace and to reduce the cost of translating effective cancer treatments to the patient. The WIN Consortium is chaired by John Mendelsohn, M.D., University of Texas - MD Anderson Cancer Center, and is based at Cancer Institute Gustave Roussy in Paris.


For further information, please contact:

Vladimir Lazar, Chief Operating Officer

Catherine Bresson, Director Operational Team,